Jefferies

NEW YORK (GenomeWeb) – Nanosphere said after the close of the market on Thursday that it is exploring potential strategic alternatives and has hired Jefferies as an advisor.

NEW YORK (GenomeWeb News) – Investment bank Jefferies today downgraded Myriad Genetics and Cepheid to Hold from Buy.

NEW YORK (GenomeWeb News) – Investment bank Jefferies today upgraded shares of Sequenom to Buy following a survey of US commercial payors that suggests the San Diego-based firm is gaining "meaningful traction" in getting coverage for its MaterniT21 Plus LDT test.

"CMS is the decision-maker here regarding fee schedule placement [of genetic tests] and we are pleased they are recognizing the importance … of having stakeholders provide input on the questions they've asked," said David Mongillo, vice president for policy and medical affairs at the American Clinical Laboratory Association.

The investment firm lowered revenue estimates and the share-price target for Nanosphere following the FDA's denial of the company's Plavix metabolism test.

CFO Roger Moody talked up Nanosphere's test for Plavix metabolism and other tests in the company's pipeline at the Jefferies Global Healthcare Conference.

Sequenom reiterated its plans to launch its T21 test by the end of the year as an LDT, while Agilent is looking to move into the top ranks as a life science instrument vendor.

Gen-Probe sees growth opportunities with its Panther platform and tests for STDs, trichomonas, HPV, and blood screening.

Pages

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.